O	0	1	A
O	2	12	randomized
O	13	20	control
O	21	26	study
O	27	29	of
O	30	38	treating
O	39	48	secondary
O	49	54	stage
O	55	57	II
O	58	64	breast
O	65	71	cancer
O	71	72	-
O	72	79	related
O	80	91	lymphoedema
O	92	96	with
B-intervention	97	101	free
I-intervention	102	107	lymph
I-intervention	108	112	node
I-intervention	113	121	transfer
O	121	122	.

O	123	136	Microsurgical
O	137	147	techniques
O	148	151	are
O	152	164	increasingly
O	165	169	used
O	170	173	for
O	174	182	treating
O	183	189	severe
O	190	201	lymphoedema
O	202	207	cases
O	207	208	.

O	209	212	The
O	213	220	purpose
O	221	223	of
O	224	228	this
O	229	234	study
O	235	238	was
O	239	241	to
O	242	250	evaluate
O	251	254	the
O	255	268	effectiveness
O	269	271	of
O	272	276	free
O	277	289	vascularized
O	290	295	lymph
O	296	300	node
O	301	309	transfer
O	310	311	(
O	311	314	LNT
O	314	315	)
O	316	318	in
B-eligibility	319	324	stage
I-eligibility	325	327	II
I-eligibility	328	334	breast
I-eligibility	335	341	cancer
I-eligibility	341	342	-
I-eligibility	342	349	related
I-eligibility	350	361	lymphoedema
I-eligibility	362	370	patients
O	371	373	in
O	374	384	comparison
O	385	389	with
O	390	393	non
O	393	394	-
O	394	402	surgical
O	403	413	management
O	413	414	.

O	415	421	During
O	422	425	the
O	426	430	last
O	431	432	3
O	433	438	years
O	438	439	,
O	440	442	83
O	443	449	female
O	450	458	patients
O	459	463	were
O	464	472	examined
O	473	475	at
O	476	479	our
O	480	491	lymphoedema
O	492	498	clinic
O	498	499	.

O	500	507	Finally
O	507	508	,
B-total-participants	509	511	36
O	512	517	cases
O	518	522	were
O	523	531	included
O	532	534	in
O	535	539	this
O	540	545	study
O	546	549	and
O	550	558	randomly
O	559	566	divided
O	567	569	in
O	570	573	two
O	574	580	groups
O	580	581	:
O	582	587	group
O	588	589	A
O	590	598	patients
O	599	600	(
O	600	601	n
O	602	603	=
B-intervention-participants	604	606	18
O	606	607	,
O	608	612	mean
O	613	616	age
B-age	617	619	47
I-age	620	625	years
O	625	626	)
O	627	636	underwent
B-intervention	637	650	microsurgical
I-intervention	651	654	LNT
I-intervention	654	655	;
I-intervention	656	664	followed
I-intervention	665	667	by
I-intervention	668	669	6
I-intervention	670	676	months
I-intervention	677	679	of
I-intervention	680	693	physiotherapy
I-intervention	694	697	and
I-intervention	698	709	compression
O	709	710	,
O	711	716	while
O	717	722	group
O	723	724	B
O	725	733	patients
O	734	735	(
O	735	736	n
O	737	738	=
B-control-participants	739	741	18
O	741	742	,
O	743	747	mean
O	748	751	age
B-age	752	754	49
I-age	755	760	years
O	760	761	)
O	762	766	were
O	767	774	managed
O	775	777	by
B-control	778	791	physiotherapy
I-control	792	795	and
I-control	796	807	compression
I-control	808	813	alone
O	814	817	for
O	818	819	6
O	820	826	months
O	826	827	.

O	828	836	Patients
O	837	839	of
O	840	844	both
O	845	851	groups
O	852	859	removed
O	860	865	their
O	866	873	elastic
O	874	882	garments
O	883	888	after
O	889	890	6
O	891	897	months
O	898	901	and
O	902	906	were
O	907	909	re
O	909	910	-
O	910	918	examined
O	919	920	1
O	921	925	year
O	926	931	later
O	931	932	.

O	933	936	All
O	937	940	the
B-total-participants	941	943	36
O	944	952	patients
O	953	956	had
O	957	965	detailed
O	966	976	evaluation
O	977	979	of
O	980	983	the
O	984	992	affected
O	993	1002	extremity
O	1003	1012	including
O	1013	1017	limb
O	1018	1024	volume
O	1025	1036	measurement
O	1036	1037	,
O	1038	1047	infection
O	1048	1056	episodes
O	1057	1060	and
O	1061	1066	scale
O	1067	1074	scoring
O	1075	1077	of
O	1078	1082	pain
O	1082	1083	,
O	1084	1091	feeling
O	1092	1094	of
O	1095	1104	heaviness
O	1105	1108	and
O	1109	1119	functional
O	1120	1126	status
O	1127	1131	both
O	1132	1134	at
O	1135	1143	baseline
O	1144	1147	and
O	1148	1150	18
O	1151	1156	month
O	1156	1157	.

B-outcome	1158	1162	Limb
I-outcome	1163	1169	volume
I-outcome	1170	1179	reduction
O	1180	1183	was
O	1184	1192	observed
O	1193	1195	in
O	1196	1200	both
O	1201	1207	groups
O	1207	1208	;
O	1209	1213	mean
O	1214	1223	reduction
O	1224	1227	was
O	1228	1235	greater
O	1236	1238	in
O	1239	1244	group
O	1245	1246	A
O	1247	1248	(
B-iv-bin-percent	1248	1250	57
I-iv-bin-percent	1251	1252	%
O	1252	1253	)
O	1254	1258	than
O	1259	1261	in
O	1262	1267	group
O	1268	1269	B
O	1270	1271	(
B-cv-bin-percent	1271	1273	18
I-cv-bin-percent	1274	1275	%
O	1275	1276	)
O	1276	1277	.

B-outcome	1278	1287	Infection
I-outcome	1288	1296	episodes
O	1297	1299	in
O	1300	1305	group
O	1306	1307	A
O	1308	1312	were
O	1313	1326	significantly
O	1327	1334	reduced
O	1335	1343	compared
O	1344	1346	to
O	1347	1352	those
O	1353	1355	in
O	1356	1361	group
O	1362	1363	B
O	1364	1372	patients
O	1372	1373	.

O	1374	1377	All
O	1378	1383	group
O	1384	1385	A
O	1386	1394	patients
O	1395	1403	reported
O	1404	1412	painless
O	1413	1416	and
O	1417	1424	feeling
O	1425	1427	of
O	1428	1437	heaviness
O	1437	1438	-
O	1438	1442	free
O	1443	1454	extremities
O	1455	1459	with
O	1460	1467	overall
O	1468	1478	functional
O	1479	1490	improvement
O	1490	1491	,
O	1492	1497	while
O	1498	1501	the
O	1502	1515	corresponding
O	1516	1523	changes
O	1524	1526	in
O	1527	1532	group
O	1533	1534	B
O	1535	1543	patients
O	1544	1548	were
O	1549	1551	no
O	1552	1556	more
O	1557	1561	than
O	1562	1570	marginal
O	1570	1571	.

O	1572	1580	Moreover
O	1580	1581	,
O	1582	1585	the
O	1586	1589	LNT
O	1590	1599	procedure
O	1600	1603	was
O	1604	1613	estimated
O	1614	1616	as
O	1617	1621	cost
O	1622	1631	effective
O	1632	1640	compared
O	1641	1643	to
O	1644	1656	conservative
O	1657	1666	treatment
O	1667	1672	alone
O	1672	1673	.

O	1674	1677	LNT
O	1678	1688	represents
O	1689	1691	an
O	1692	1701	effective
O	1702	1713	therapeutic
O	1714	1722	approach
O	1723	1726	for
O	1727	1732	stage
O	1733	1735	II
O	1736	1747	lymphoedema
O	1748	1756	patients
O	1756	1757	;
O	1758	1760	it
O	1761	1774	significantly
O	1775	1782	reduces
O	1783	1787	limb
O	1788	1794	volume
O	1794	1795	,
O	1796	1805	decreases
O	1806	1815	recurrent
O	1816	1826	infections
O	1827	1830	and
O	1831	1839	improves
O	1840	1843	the
O	1844	1851	overall
O	1852	1860	function
O	1860	1861	.
